Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 27;17(1):284.
doi: 10.1186/s13256-023-03950-w.

Pure tubular carcinoma of the breast: a case series

S Sakhri  1 , M Aloui  2 , I Zemni  1 , S Kamoun  3 , M Slimene  1 , K Rahal  1
Affiliations
Review

Pure tubular carcinoma of the breast: a case series

S Sakhri et al. J Med Case Rep. .

Abstract

Background: Pure tubular breast carcinoma is a rare and well-differentiated tumor with high survival and low local recurrence rate. Our study aims to determine the clinical, radiological, appropriate management, and prognosis of this carcinoma.

Materials and methods: A review of Salah Azaiez institute registry from 2004 to 2019 was performed including seven cases of PTC of the breast.

Results: Clinical-pathologic features and outcomes were analyzed. The median follow-up was 3 years. In our study, we found that the cohort presented more frequently with pT1 disease and pN0 disease. Conservative surgery was more frequently indicated (five cases). All patients had hormone-receptor positivity and Human Epidermal growth factor Receptor 2 (HER2) negativity. The majority of tumors had a molecular profile luminal A and a low-grade SBR. In one case we found axillary lymph node metastasis. Adjuvant radiotherapy was indicated in all cases of breast conservation and in only one case of radical surgery. One patient received chemotherapy. The mean follow-up was 4 years. We did not find any local or distant recurrence in our study.

Conclusion: PTC showed an excellent prognosis with a low SBR grade, a molecular profile luminal A, and a low incidence of recurrence.

Keywords: Adjuvant treatment; Prognosis; Pure tubular breast carcinoma; Radiology; Surgery.

PubMed Disclaimer

Conflict of interest statement

No conflicts of interest between the author and this work are present, with all due respect to the code of ethics under the supervision of the medical and ethic committee of the Salah Azaiez Institute.

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Hematoxylin and eosin (HE) × 100: well-differentiated tubules surrounded by an abundant fibrous stroma
Fig. 2
Fig. 2
IHC × 100 RE showing positive and diffuse staining for estrogen receptors
Fig. 3
Fig. 3
IHC × 100: HER2 showing negative staining with positive external control at the bottom left
Fig. 4
Fig. 4
IHC for Ki67 showing a low Ki67 proliferation index (5%)
See this image and copyright information in PMC

References

    1. Shin HJ, Kim HH, Kim SM, Kim DB, Lee YR, Kim MJ, et al. Pure and mixed tubular carcinoma of the breast: mammographic and sonographic differential features. Korean J Radiol. 2007;8(2):103–110. doi: 10.3348/kjr.2007.8.2.103. - DOI - PMC - PubMed
    1. Romano AM, Wages NA, Smolkin M, Fortune KL, Atkins K, Dillon PM. Tubular carcinoma of the breast: institutional and SEER database analysis supporting a unique classification. Breast Dis. 2015;35(2):103–111. doi: 10.3233/BD-140396. - DOI - PubMed
    1. Chen JX, Zhang WW, Dong Y, Sun JY, He ZY, Wu SG. The effects of postoperative radiotherapy on survival outcomes in patients under 65 with estrogen receptor positive tubular breast carcinoma. Radiat Oncol. 2018;13(1):226. doi: 10.1186/s13014-018-1177-9. - DOI - PMC - PubMed
    1. Min Y, Bae SY, Lee HC, Lee JH, Kim M, Kim J, et al. Tubular carcinoma of the breast: clinicopathologic features and survival outcome compared with ductal carcinoma in situ. J Breast Cancer. 2013;16(4):404–409. doi: 10.4048/jbc.2013.16.4.404. - DOI - PMC - PubMed
    1. Tubular breast cancer, Breast Cancer Now. Disponible sur: https://breastcancernow.org/information-support/facing-breast-cancer/dia.... Accessed 31 Mar 2023.